MedPath

Addition of oral thalidomide to standard antitubercular regimen for initial 2 months improves the outcome in patients of tubercular meningitis as compared to standard therapy alone.

Not Applicable
Conditions
Health Condition 1: A170- Tuberculous meningitis
Registration Number
CTRI/2020/08/027438
Lead Sponsor
AIIMS Bhubaneswar
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Clinically diagnosed new cases of tuberculous meningitis using clinical, CSF and radiological finding.

2.Within one month of starting anti tubercular treatment.

3.Willing to participate in study by signing informed consent.

4. Age 18 year or older of both sexes.

Exclusion Criteria

1.Confirmed meningitis other than TB

2.Pregnancy.

3.Pre-existing neuropathy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath